SCHEMBL24252348

SCHEMBL24252348

COc1cc(C#N)c(B(O)O)cc1-c1ccc2c(N)nnc(C)c2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.36
AR P10275 1/20 0.36
KDM4E B2RXH2 6/20 0.35
ALDH1A1 P00352 3/20 0.35
PLAU P00749 1/20 0.35
ADORA2A P29274 2/20 0.35
ADORA1 P30542 2/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
PRKCZ Q05513 1/20 0.34
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
GFER P55789 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
XDH P47989 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
S1PR1 P21453 1/20 0.34
PRMT5 O14744 1/20 0.33
WDR77 Q9BQA1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL25266826 0.95 XDH (0.33) PGRARKDM4EALDH1A1PLAU
Formic Acid SCHEMBL30451260 0.95 XDH (0.33) PGRARKDM4EALDH1A1PLAU
SCHEMBL26771301 0.94 PGR (0.34) PGRARKDM4EALDH1A1PLAU
SCHEMBL25211820 0.89 XDH (0.32) PGRARKDM4EALDH1A1PLAU
SCHEMBL24252646 0.85 DHFR (0.36) ALDH1A1PLAUMEN1KMT2ATDP1
SCHEMBL30451530 0.84 FYN (0.34) KDM4EPRKCZTDP1DHFR
SCHEMBL30451987 0.84 PLAU (0.36) PLAUADORA2AADORA1DHFR
SCHEMBL24252368 0.84 PLAU (0.36) PLAUADORA2AADORA1DHFR
SCHEMBL24252645 0.84 FYN (0.34) KDM4EPRKCZTDP1DHFR
SCHEMBL24252276 0.82 ABL1 (0.33) PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 PGR 3293/4885AR 4756/4885KDM4E 3923/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 PGR 3293/4885AR 4756/4885KDM4E 3923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.